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Summary 30 
Telomere dysfunction is implicated in the generation of large-scale genomic rearrangements 31 
which drives progression to malignancy. In this study we used high-resolution single 32 
telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 33 
Myelodysplasia (MDS) and 95 de novo Acute Myeloid Leukaemia (AML) patients. Despite 34 
the MDS cohort being older they had significantly longer telomeres than the AML cohort (P 35 
<.0001) where telomere length was also significantly shorter in younger AML patients (age 36 
<60) (P = .02) and in FLT3 ITD mutated AML patients (P = .03). Using a previously determined 37 
telomere length threshold for telomere dysfunction (3.81kb) did not provide prognostic 38 
resolution in AML (HR = 0.68, P = .2). In contrast, the same length threshold was highly 39 
prognostic for overall survival in the MDS cohort (HR = 5.0, P <.0001). Furthermore, this 40 
telomere length threshold was an independent parameter in multivariate analysis when 41 
adjusted for age, gender, cytogenetic risk group, number of cytopenias and IPSS score (HR = 42 
2.27, P < .0001). Therefore, telomere length should be assessed in a larger prospective study 43 
to confirm its prognostic role in MDS with a view to integrating this variable into a revised 44 
IPSS.  45 
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Introduction 46 
The Myelodysplastic Syndromes (MDS) are a heterogeneous group of clonal haematopoietic 47 
disorders with varying survival and propensity to develop secondary acute myeloid 48 
leukaemia (sAML). In 1997 the International Prognostic Scoring System (IPSS) was based on 49 
the bone marrow blast count, 3 distinct cytogenetics risk groups and the number of 50 
cytopenias dividing patients into four IPSS subgroups(Greenberg, et al 1997). The IPSS – R 51 
(Revised) is an updated refinement of the IPSS which identifies five cytogenetic, three 52 
cytopenic and four blast count risk categories which combine into five overall prognostic 53 
subgroups(Greenberg, et al 2012, Vardiman, et al 2009). Many MDS patients have a normal 54 
karyotype but in recent years a very large number (up to 660) of molecular genetic defects 55 
have been identified encoding genes for cellular proteins including transcription factors e.g. 56 
RUNX1, epigenetic regulators and chromatin remodelling factors e.g. TET2, DNMT3A, 57 
IDH1/2, pre-RNA splicing factors e.g. SF3B1, receptor tyrosine kinase/ signalling molecules 58 
e.g. NRAS, JAK2, NPM1,FLT3 and check point regulator P53 some of which impact 59 
significantly on prognosis (Tothova, et al 2013, Walter, et al 2012). A recent MDS study 60 
showed that some of these somatic mutations were an independent prognostic marker 61 
compared to the IPSS  (Bejar, et al 2011). 62 
Recent studies have shown that the same genomic mutations seen in MDS/AML patients 63 
overlap with those identifiable in the normal adult population with increasing frequency 64 
with age (Genovese, et al 2014, Jaiswal, et al 2014, McKerrell, et al 2015, Xie, et al 2014). 65 
What drives these clones to further genomic instability and the development of MDS/AML is 66 
currently poorly understood. Telomeres are repetitive DNA sequences at the ends of 67 
chromosomes that shorten with each cell division. Critical loss of telomere length leads to 68 
chromosome end-end fusion and genomic instability resulting in large scale re-69 
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arrangements such as non-reciprocal translocations which are the hallmark of many tumour 70 
types including MDS, sAML and de novo AML (Jones, et al 2012). With ongoing cell division 71 
during life, the telomeres in normal individuals erode as a function of age at a rate of 72 
approximately 26 bp/year(Daniali, et al 2013). Several studies have suggested that MDS is 73 
associated with shorter telomeres leading to genomic instability and progression to sAML 74 
(Boultwood, et al 1997, Chakraborty, et al 2009, Sieglova, et al 2004, Townsley, et al 2014, 75 
Young 2010). Recently, using a modified Q-FISH based method, Gadji et al proposed that 76 
telomere dysfunction underpins the chromosomal changes associated with MDS 77 
progression to AML and de novo AML (Gadji, et al 2012). Whilst in a mouse model it was 78 
shown that telomere dysfunction induced the same types of DNA damage that drives 79 
classical MDS phenotypes including SF3B1 and DNMT3A resulting in differentiation changes 80 
in myeloid precursors (Colla, et al 2015). 81 
We previously developed a high-resolution technique to determine telomere length, Single 82 
Telomere Length Analysis (STELA), which is unique in its ability to detect telomere lengths 83 
from single chromosomes within the length ranges at which telomere fusions can occur (Lin, 84 
et al 2010, Lin, et al 2014). Using STELA we have shown that some chronic lymphocytic 85 
leukaemia (CLL) patients display extreme telomere shortening and fusion consistent with 86 
the onset of a telomere-driven crisis that can drive the formation of large-scale genome 87 
rearrangements(Lin, et al 2010). Telomeres in these ranges cannot be readily detected with 88 
the other methodologies such as QPCR, Southern blot or Q-FISH previously used in 89 
MDS/AML studies (Baird, et al 2003, Britt-Compton, et al 2012, Chakraborty, et al 2009, Lin, 90 
et al 2010). We showed that in CLL patients, telomere fusions only occurred when telomere 91 
length was ≤3.81 kb and importantly we show that telomere erosion to within these length 92 
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ranges precedes clinical progression. Indeed high-resolution telomere length analysis using 93 
STELA, together with the stratification of patients based on the telomere length thresholds 94 
at which fusion occurs, provided an independent high-resolution marker of prognosis even 95 
in patients with early-stage CLL (Lin, et al 2014). 96 
In this study we used STELA to assess if telomere erosion is an important pathogenic 97 
mechanism driving prognosis MDS and AML.  98 
Methods 99 
Patients, samples and cell separation 100 
This study was undertaken at the University Hospital of Wales (UHW), Cardiff. All of the 101 
unselected diagnostic patient bone marrow samples: 80 MDS which consisted of 37 samples 102 
from Dundee (archived from 1997 – 2005) and 43 from Cardiff (archived between 1985 and 103 
2008) including 7 with a proven and documented history of MDS prior to progression to 104 
AML (blasts >20%), and 95 de novo AML from Cardiff (archived between 2003 and 2012) 105 
were obtained following written informed consent (Table 1). We deliberately chose to use 106 
stored but well annotated archival samples so as to be able to assess the potential impact of 107 
telomere length on survival in all patient groups but especially low risk MDS patients. All 108 
MDS patients were treated with best supportive care with none receiving azacitidine prior 109 
to this analysis.  All morphological, immunophenotypic, cytogenetic and molecular data 110 
were collected from Cardiff and Dundee Haematology Departments for their respective 111 
patients but all telomere length analyses on the bone marrow mononuclear cells were 112 
undertaken within the Division of Cancer and Genetics, Cardiff University. Bone marrow 113 
mononuclear cells were collected in ethylenediaminetetraacetic acid and isolated by 114 
density centrifugation using Ficoll-Hypaque (Invitrogen) which resulted in <3% 115 
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lymphocytes contamination. Cells were stored at −20°C as dry pellets before DNA 116 
extraction. 117 
DNA extraction, single telomere length analysis and telomerase assays. 118 
Telomere length was determined using XpYp STELA as previously described (Lin, et al 119 
2010, Roger, et al 2013). Briefly, DNA was extracted using proteinase K, RNase A, 120 
phenol/chloroform protocols and quantified by Hoechst 33258 fluorometry (Bio-Rad) 121 
before dilution to 10 ng/μL in 10mM Tris-HCl, pH 7.5. A total of 10 ng of DNA was further 122 
diluted to 250 pg/μL in a volume of 40 μL containing 1μM Telorette2 linker and 1mM Tris-123 
HCl, pH 7.5. Multiple polymerase chain reactions (PCRs; typically 6 reactions per sample) 124 
were carried out for each test DNA in 10-μL volumes 250 pg of DNA, 0.5μM of the 125 
telomere-adjacent and Teltail primers, 75mM Tris-HCl, pH 8.8, 20mM (NH4)2SO4, 0.01% 126 
Tween-20, 1.5mM MgCl2, and 0.5 U of a 10:1 mixture of Taq (ABGene) and Pwo 127 
polymerase (Roche Molecular Biochemicals). The reactions were cycled with an MJ PTC-128 
225 thermocycler (MJ Research). The DNA fragments were resolved by 0.5% Tris acetate 129 
ethylenediaminetetraacetic acid agarose gel electrophoresis, and detected by Southern 130 
blot hybridization with random-primed α-
33
P–labelled (GE Healthcare) TTAGGG repeat 131 
probe together with probes to detect the 1-kb (Stratagene) and 2.5-kb (Bio-Rad) 132 
molecular weight markers. The hybridized fragments were detected by phosphorimaging 133 
with a Molecular Dynamics Storm 860 phosphorimager (GE Healthcare). The molecular 134 
weights of the DNA fragments were calculated using the Phoretix 1D quantifier (Nonlinear 135 
Dynamics). Telomerase assays were undertaken using the TRAPeze XL Telomerase 136 
detection kit (Chemicon International, Billerica, MA) as previously described (Lin, et al 137 
2010, Roger, et al 2013). 138 
Page 6 of 26British Journal of Haematology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Telomere length is prognostic in MDS but not AML 
Version 3 06/1/17 Page 7 
  
Statistical methods 139 
Statistical analysis was undertaken by the Haematology Clinical Trials Unit, Cardiff University 140 
using SAS version 9.4 and GraphPad Prism 6. Spearman’s correlation was used for 141 
correlations between baseline values; Mann-Whitney and Wilcoxon matched-paired 142 
nonparametric tests were used for comparisons between groups. Mean telomere length 143 
was assessed between diagnoses using the Wilcoxon rank sum test. Paired data were 144 
compared using the Wilcoxon signed rank test. In the MDS cohort patients were assessed 145 
using the 1997 IPSS criteria for  the 3 cytogenetic risk groups, blast count, number of 146 
cytopenias (Hb <100g/l, neutrophils <1.5x10
9
/l and platelets <100x10
9
/l), IPSS score, age  147 
and sex whereas the AML cohort was assessed for cytogenetic risk group and FLT3 and 148 
NPM mutations (Falini, et al 2005, Kottaridis, et al 2001, Townsley, et al 2014). Survival 149 
was assessed using the Kaplan-Meier method, and compared using Cox proportional 150 
hazards regression, with model building carried out using forward selection with significance 151 
set at P = .05. 152 
Results  153 
Telomere length MDS and AML patients. 154 
An MDS patient’s bone marrow will typically display a variable range of immature and more 155 
differentiated cells which may or may not be derived from the malignant stem cells. We 156 
therefore compared the telomere length of the first 20 individual MDS patients CD34+ and 157 
CD34- bone marrow cells, but found no significant difference in telomere length between 158 
the two fractions (P = .08; Supplementary Figure 1A). We therefore proceeded without cell 159 
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selection in subsequent MDS patient bone marrow sample analyses and simply used bone 160 
marrow mononuclear cell pellets.  161 
Despite the fact that the MDS patients (median age 68 years, range 21-86) were older than 162 
AML patients (median age 56 years, range 17-80) telomere length was significantly longer in 163 
the MDS cohort compared to the AML cohort (P < .0001; Figure 1A). Although MDS samples 164 
showed a modest reduction in telomere length with increasing age at diagnosis, there was 165 
no significant correlation (ρ
2
 = -.0212, P = .2; Figure 1B) whereas in the AML samples a 166 
positive correlation was observed (ρ
2
 = .0890, P = .003; Figure 1C). This finding is in contrast 167 
to what occurs during normal ageing; samples derived from older AML patients (age >60) 168 
had significantly longer telomeres than younger AML patients (P = .02; Figure 1D). Indeed, 169 
22/26 (84.6%) of AML patients age <50 years had telomere lengths within the range at 170 
which they can become dysfunctional or ‘fusogenic’ (≤3.81 kb), which we previously 171 
described in CLL (Lin, et al 2014). 172 
 173 
Telomere length, blast count, cytogenetics, cytopenias and IPSS. 174 
We next analysed the MDS cohort to assess any possible correlations between telomere 175 
length and age, gender, blast count, number of cytopenias, cytogenetic risk group and IPSS 176 
sub-group. Shorter telomere length was associated with male gender (P = .01; 177 
Supplementary Figure 1B) and increased number of cytopenias (P = .003; Figure 2A).  None 178 
of the other parameters were significantly associated with telomere length. Consistent with 179 
previous reports we found a significant association between the number of cytopenias and 180 
overall survival (P < .0001; Supplementary Figure 2A). Furthermore, patients with high risk 181 
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cytogenetic abnormalities tended to have worse survival although this did not reach 182 
statistical significance (P = .12; Supplementary Figure 2B).  Interestingly we found no simple 183 
association between telomere length and the three IPSS cytogenetic risk groups (P = .6 for 184 
trend; Figure 2B), the four IPSS subgroups (ρ
2
 = .14 for correlation; Figure 2C) or bone 185 
marrow blast percentage (ρ
2 
=-0.22, P = .0503 Figure 2D).  186 
In the de novo AML cohort we assessed the correlation between telomere length and 187 
gender, age, presenting WBC, performance status, whether primary or secondary AML and 188 
NPM1 and FLT3 mutation status. There was no association between NPM1 mutated patients 189 
and telomere length (data not shown), but significantly shorter telomeres were found in the 190 
FLT3 ITD mutated group when compared to FLT3 wild type AML patients (P = .03). In 191 
contrast, there was a trend towards longer telomeres in the FLT3 TKD mutated group 192 
compared to ITD mutated AML (P = .12; Figure 2E). 193 
 194 
Telomerase activity in MDS and AML patients.  195 
Given the different telomere length characteristics of the MDS and AML cohorts, we 196 
investigated whether this may reflect differences in telomerase activity, an enzyme 197 
responsible for extending shortened telomeres. Telomerase activity was analysed in a 198 
subset of CD34+ AML samples (n = 12) and in purified CD34+ cells from MDS patients (n = 199 
20). Telomerase activity was significantly higher in the AML samples when compared with 200 
CD34+ MDS cells (P = .0002; Figure 2F). 201 
 202 
Telomere length and survival in MDS and AML. 203 
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We next assessed the impact of telomere length on overall survival in the MDS and AML 204 
cohorts. Segregation of the two cohorts according to whether their mean telomere length 205 
was above or below the upper limit of telomere dysfunction (3.81 kb) revealed no 206 
difference in survival in the AML patient group (HR = 0.68 (0.37-1.9), P = .2; Figure 3A). In 207 
contrast, bifurcation of the MDS cohort using this threshold telomere length demonstrated 208 
that patients with a median telomere length ≤3.81 kb had significantly worse survival (HR = 209 
5.0 (2.7-10.0), P< .0001; Figure 3B). The impact of telomere length in these two disease 210 
settings was confirmed using telomere length quartile analysis. There was no correlation 211 
between telomere length and overall survival or relapse-free survival in the AML cohort (P = 212 
.5, P = .09; Supplementary Figures 3A and 3B). However, similar quartile analysis in the MDS 213 
cohort clearly showed that patients in the lowest two quartiles had worse survival with all 214 
patients in the lowest quartile alive at 3 years (Supplementary Figure 3C).  215 
 216 
Telomere length is an independent prognostic variable in MDS. 217 
Finally, we performed multivariate analysis in the MDS cohort using a forward selection 218 
model that included age, IPSS, gender, cytogenetic risk group, number of cytopenias and 219 
telomere length. Short telomere length was identified as the most significant independent 220 
marker of overall survival (HR = 2.27 (1.45-3.57), P< .0001). When entering short telomere 221 
length into the model the following parameters retained independent prognostic value: high 222 
IPSS (HR = 1.2 (0.64-2.27), increased number of cytopenias (HR = 1.60 (1.09-2.35), P = .007), 223 
older age (HR per year 1.03 (1.01-1.07), P = .05) and male gender (HR = 2.70 (1.20-6.10), P = 224 
.01).    225 
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 226 
 227 
 228 
Discussion 229 
We previously showed that a proportion of chronic lymphocytic leukaemia (CLL) 230 
patients display extreme telomere erosion and fusion consistent with a telomere-driven 231 
crisis. Importantly, this was not simply a function of advanced stage disease but was 232 
detected in a subset of early stage patients prior to clinical progression (Lin, et al 2010). 233 
Subsequently we showed that defining the specific telomere length threshold at which 234 
telomere fusion occurred was a powerful way to risk-stratify CLL patients even those with 235 
early-stage disease (Lin, et al 2014). Previous studies had suggested a possible role for 236 
telomere dysfunction in both MDS and AML, so here we investigated the relationship 237 
between telomere length, disease progression and clinical outcome in MDS and AML using 238 
the high-resolution STELA technique. 239 
We demonstrated that telomere length was highly predictive of disease outcome in MDS. In 240 
contrast, we found no evidence that telomere length influenced the survival of de novo AML 241 
patients. It should be noted, however, that we demonstrated shorter telomere lengths in 242 
the FLT3-ITD mutated group, a group with a well-established poorer prognosis. These results 243 
are similar to those of Aalbers et al who also showed shorter telomeres in patients with 244 
FLT3-ITD mutations but not NPM1 mutated patients (Aalbers, et al 2013). One possible 245 
explanation for the different telomere length characteristics in MDS and AML may be the 246 
differential expression of telomerase found in these two conditions. Unlike MDS cells, AML 247 
cells showed evidence of upregulated telomerase activity, which could prevent replicative 248 
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senescence and allow unlimited proliferation during leukaemogenesis (Engelhardt, et al 249 
2004, Shay and Wright 2011). MDS is characterised by clonal expansion and hypercellularity 250 
but increased apoptosis leading to cytopenias (Greenberg 1999, Greenberg 1998, Parker, et 251 
al 1998, Parker and Mufti 2000). The reason why telomerase is not upregulated in MDS is 252 
unknown, but to date studies have failed to show any responsible acquired telomerase-253 
regulated genetic abnormalities in this patient group, although there are several germline 254 
mutations described in TERC and TERT predisposing to MDS/AML (Ballew and Savage 2013, 255 
Calado, et al 2009, Kirwan, et al 2009, Ohyashiki, et al 1999, Yamaguchi, et al 2003). 256 
Our study showed an association between telomere length and the number of cytopenias in 257 
MDS patients. It seems possible that the lack of telomerase activity observed in MDS leads 258 
to unhindered cell senescence and/or apoptosis. Also the high proliferative and apoptotic 259 
rates seen in MDS bone marrow produces increased ineffective haematopoiesis and more 260 
profound cytopenias (Raza, et al 1997a, Raza, et al 1997b).  These results are similar to 261 
those of Sieglova et al who showed MDS patients with shorter telomeres were more likely 262 
to progress to AML (Sieglova, et al 2004). Perhaps surprisingly, there was no association 263 
between telomere length and cytogenetic risk group, blast count and IPSS score. This lack of 264 
association meant that telomere length was an independent marker of outcome in MDS and 265 
in the multivariate forward selection model we employed. Indeed, it was more prognostic 266 
than blast count, cytogenetics, number of cytopenias or IPSS in this context.  267 
Several recent studies have shown that clonal haematopoiesis is almost a “normal” part of 268 
ageing with recent reports showing 0.8%, 11% and 19.5 % of normal individuals aged <60, 269 
>80 and >90 years respectively having demonstrable clonal haematopoiesis – so called age-270 
related clonal haematopoiesis.  These include the acquisition of many genetic lesions 271 
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associated with the development of MDS/AML including DNMT3, IDH1, IDH2, NRAS, KRAS, 272 
JAK 2, SF3B1 and SRSF2 mutations (Jaiswal, et al 2014, McKerrell, et al 2015, Xie, et al 2014). 273 
Three of our observations in this study were that the telomere length increases with age in 274 
AML patients, that AML patients older than 60 years having significantly long telomeres 275 
than those age <60 years and that the AML patient cohort had significantly shorter 276 
telomeres than the MDS patient cohort despite being younger. One possible explanation for 277 
these data is that older de novo AML patients may have developed secondary AML despite 278 
the absence of a documented history of prior MDS or clonal haematopoiesis. This would be 279 
in keeping with the recent identification of increased genomic instability in ageing “normal” 280 
people with many identical genomic abnormalities seen in elderly AML patients (McKerrell, 281 
et al 2015).  The acquisition of the various differing leukaemia-associated genomic 282 
abnormalities are age dependent with for example the recurrent point mutations affecting 283 
spliceosome genes SF3B1 and SRSF2 associated with clonal haematopoiesis in individuals 284 
aged 70 years or over, but not in younger people (McKerrell and Vassiliou 2015, 285 
Papaemmanuil, et al 2013). An alternative, but not exclusive hypothesis, is that AML in 286 
younger patients tends be more progenitor-type AML (Core binding factor, NPM1-mutated, 287 
FLT3-ITD-mutated) and more proliferative leading to shorter telomeres.  Further studies are 288 
required to assess the relationship of shorter telomeres with age-related clonal 289 
haematopoiesis and MDS and AML development. 290 
The findings in MDS are in keeping with our previous data in CLL and breast cancer where 291 
we demonstrated the utility of our telomere-length threshold in providing powerful 292 
independent prognostic information (Lin, et al 2014, Roger, et al 2013). Taken together 293 
these data point to a common mechanism that is present in diverse tumour types, by which 294 
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the presence of short dysfunctional telomeres can drive genomic instability and clonal 295 
evolution leading to poor clinical outcomes. 296 
Our study does have several limitations in that it consists of relatively small cohorts of MDS 297 
and AML patients and was deliberately retrospective so as to be able to assess the impact of 298 
telomere length on survival especially in low risk MDS patients, all of whom were treated 299 
with supportive care only. Finally our observation that telomere length is independently 300 
prognostic in MDS indicates that consideration should be given to a much larger prospective 301 
study assessing the potential role of telomeres in the prognostication of MDS. This would 302 
also facilitate the assessment of telomere length analysis as a potential predictor of 303 
response to newer therapies such as azacitidine and perhaps its ultimate incorporation into 304 
a revised IPSS. 305 
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 505 
Figures and Legends. 506 
 507 
Table 1. Demographics of MDS and AML Cohorts 508 
 509 
Figure 1. (A) Telomere length in the MDS cohort was significantly longer than those of the 510 
AML cohort despite being older median age 68 v 56 years (p < .0001). B) In MDS patients 511 
there was no correlation between telomere length and age of diagnosis (ρ
2
 = .0212; P = .2). 512 
(C) In AML patients there was a positive correlation between telomere length and age of 513 
diagnosis (ρ
2
 = .0890; P = .003). (D) Older AML patients (age >60) had significantly longer 514 
telomeres than younger patients (P =.02). 515 
 516 
Figure 2. (A) In the MDS cohort there was a significant association between the telomere 517 
length and the number of cytopenia but not with (B) cytogenetic risk group (P =.6 for trend) 518 
or (C) IPSS sub-groups (ρ
2
=.14 for correlation) or (D) blast counts (ρ
2
=.22 P =.503). (E) 519 
Patients with a FLT3-ITD showed significantly shorter telomeres than the FLT3-WT group 520 
(overall P = .03 and there was a trend towards shorter telomere length in the FLT3-ITD 521 
group when compared with the FLT3-TKD group (P = .12)). F) Telomerase activity was 522 
significantly higher in AML CD34 + cells compared to MDS CD34+ cells (P = .0002). 523 
 524 
Figure 3. (A)Using our previously described CLL fusogenic length threshold (TL ≤3.81 kb) 525 
there is no difference in survival in AML patients (HR = 1.47 (0.80-2.68), P = 0.2. (B) In 526 
contrast, categorization of the MDS cohort above and below the fusogenic length threshold 527 
(3.81 kb) demonstrated that MDS patients with short telomeres had an inferior survival (HR 528 
= 5.0 (2.7-10.0), P <.0001). 529 
 530 
Supplementary Figure 1. (A) In 20 MDS patients bone marrow mononuclear cells were 531 
sorted but there was no significant difference in telomere length in CD34+ and CD34 – 532 
selected sub-populations. (B) In the MDS cohort longer telomere length was associated with 533 
female sex (P = .01).  534 
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Supplementary Figure 2. (A) In the MDS cohort there was a significant association between 535 
the number of cytopenias and overall survival (P < .0001). (B) In the MDS cohort patients 536 
with high risk cytogenetic lesions tended to have worse survival although this did not reach 537 
statistical significance probably due to the relatively small sample size (P = .12). 538 
Supplementary Figure 3. Quartile analysis of telomere length revealed no significant 539 
difference in (A) overall survival and (B) relapse-free survival in the de novo AML cohort. In 540 
contrast, (C) MDS patients in the lower two telomere length quartiles showed significantly 541 
shorter overall survival.  542 
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Demographic Feature MDS Cohort (n=80) AML Cohort (n=95) 
Sex 
Male 
Female 
 
50 
30 
 
48 
47 
Age  
Median (range) 
<60 
≥60 
 
68 (21-86) 
20 
60 
 
56 (17-80) 
56 
39 
Cytogenetic Risk Group 
Good 
Intermediate 
Poor 
Failed/Not known 
 
45 
15 
15 
5 
 
6 
76 
3 
10 
Number of cytopenias 
1 
2 
3 
 
37 
15 
28 
 
Bone Marrow Blast Count 
<5% 
5-10% 
10-20% 
>20% 
 
36 
13 
24 
7 
 
IPSS Score 
High 
Intermediate-2 
Intermediate-1 
Low 
 
25 
11 
19 
25 
 
Treatment 
Intensive 
Non-intensive 
  
89 
6 
ITD 
WT 
Mutant 
Unknown 
  
49 
39 
7 
NPM1c 
WT 
Mutant 
Unknown 
  
35 
54 
6 
TKD 
WT 
Mutant 
Unknown 
  
73 
19 
3 
WBC 
Median (range) 
  
34.1 (1.3-294.0) 
Performance Status (WHO) 
0 
1 
2 
3+ 
  
54 
30 
4 
7 
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Supplementary Figure 1  
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